Physician profile
John A Power
NPI 1326007790
$5,704.57
in general payments reported to CMS, 2019-2025
27 companies · $1,171 in 2025
The $1,171 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $463 · 2020: $349 · 2021: $907 · 2022: $579 · 2023: $1,011 · 2024: $1,224 · 2025: $1,171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,316 · Education: $90.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,315.81 |
| Education | $90.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,101.94 | 2019-2025 | |
| Abbott Laboratories | $573.29 | 2021-2025 | Aveir, Jot Dx, Gallant |
| Biosense Webster, INC. | $519.01 | 2024-2025 | Carto 3 |
| Amgen INC. | $445.63 | 2019-2025 | Repatha, Repatha |
| Medtronic, INC. | $419.11 | 2023-2025 | Corevalve Evolut R, Cobalt Dr Mri Surescan, Ffrangio |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $383.88 | 2019-2025 | Lifevest |
| Amarin Pharma, INC. | $294.64 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $267.19 | 2019-2024 | Xarelto |
| Cardiva Medical, INC. | $179.23 | 2024-2025 | Cardiva Vascade Mvp Xl Vvcs 10-12f, Cardiva Vascade Mvp Vvcs 6-12f, Cardiva Vascade 6/7f Vcs |
| Edwards Lifesciences Corporation | $177.50 | 2022-2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Sapien 3 Ultra Resilia |
| Pfizer INC. | $170.85 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $143.02 | 2022-2025 | Jardiance |
| Boston Scientific Corporation | $142.76 | 2020-2025 | Watchman Flx, Farapulse |
| Astrazeneca Pharmaceuticals LP | $135.44 | 2021-2023 | Andexxa |
| Lexicon Pharmaceuticals, INC. | $116.45 | 2023 | Inpefa |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kestra Medical Technology Services, INC. | $105.28 | 2022-2025 | Assure Wcd |
| Cardiovascular Systems INC. | $86.04 | 2019-2022 | |
| Atricure, INC. | $74.97 | 2024 | |
| Philips North America LLC | $71.66 | 2024 | (Ck4) Mcot |
| E.R. Squibb & Sons, L.L.C. | $63.51 | 2022-2024 | Eliquis |
| Sanofi Pasteur INC. | $61.14 | 2019 | |
| Cordis US Corp. | $45.70 | 2024 | Mynx Control, Mynx Venous Vcd |
| Kiniksa Pharmaceuticals, LTD. | $36.05 | 2023 | Arcalyst |
| Esperion Therapeutics, INC. | $29.51 | 2021 | |
| Portola Pharmaceuticals, LLC | $24.97 | 2019 | |
| Novo Nordisk INC | $18.50 | 2023 | Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $17.30 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Power listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.